Full Press Release Details
SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development
PFE Positive Sentiment
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
Key Takeaway: Edison Scientific has entered into an agreement with Pfizer to enhance research and development initiatives. This collaboration is expected to expedite the development process, potentially leading to significant advancements in their projects. The partnership reflects a commitment to innovation in the biopharma sector.
Market Sentiment Analysis
POSITIVE FACTORS
- Edison Scientific partners with Pfizer.
- Agreement aims to accelerate R&D efforts.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
PF-07817883
Phase 2 · SARS-CoV-2 Infection
Frequently Asked Questions
What is the agreement between Edison Scientific and Pfizer?
Edison Scientific has partnered with Pfizer to accelerate research and development.
What is the goal of the partnership?
The partnership aims to enhance and expedite R&D efforts.
Where was the announcement made?
The announcement was made in San Francisco.
Who announced the agreement?
Edison Scientific announced the agreement with Pfizer.